转录调节因子FUBP1影响小鼠和人类髓系白血病的疾病结局
研究探讨转录调节因子FUBP1在慢性髓系白血病(CML)和急性髓系白血病(AML)中的作用。在小鼠模型中敲低Fubp1可延长生存、减少CML祖细胞、降低细胞周期活性并增加凋亡;FUBP1在人类CML中高表达且与疾病进展相关,在AML中高表达趋势与较短总生存相关;伊立替康联合阿糖胞苷可显著延长AML小鼠生存。
要点
- 敲低Fubp1在CML和AML小鼠模型中均延长生存。
- FUBP1在人类CML中较正常骨髓高表达,且与疾病进展相关。
- 伊立替康单用或联合阿糖胞苷显著延长AML小鼠生存。
核心结论
- 数据提示FUBP1在白血病中作为细胞周期调节因子和凋亡抑制因子起作用,可能参与DNA修复,其抑制可能改善白血病患者结局。
研究设计与样本
- 研究使用由BCR-ABL1诱导的慢性髓系白血病(CML)和由MLL-AF9诱导的急性髓系白血病(AML)小鼠模型。
- 在CML和AML细胞系中进行FUBP1敲低实验。
- 检测人类CML和AML患者白血病细胞中FUBP1表达。
- 用伊立替康治疗AML小鼠,单用或联合阿糖胞苷。
主要发现
- 在CML和AML小鼠模型中,敲低Fubp1导致生存期延长、CML祖细胞数量减少、细胞周期活性降低和凋亡增加。
- 在CML和AML细胞系中敲低FUBP1重现上述发现,并显示与表达野生型FUBP1水平的白血病细胞相比DNA损伤增强。
- FUBP1在人类CML中较正常骨髓细胞表达更高,其表达与疾病进展相关。
- 在AML中,患者白血病细胞FUBP1表达较高,与较短总生存有相关趋势。
- 伊立替康单用或与阿糖胞苷联合治疗AML小鼠均显著延长生存。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The transcriptional regulator far upstream element binding protein 1 (FUBP1) acts as an oncoprotein in solid tumor entities and plays a role in the maintenance of hematopoietic stem cells. However, its potential function in leukemia is unknown. In murine models of chronic (CML) and acute myeloid leukemia (AML) induced by BCR-ABL1 and MLL-AF9, respectively, knockdown of Fubp1 resulted in prolonged survival, decreased numbers of CML progenitor cells, decreased cell cycle activity and increased apoptosis. Knockdown of FUBP1 in CML and AML cell lines recapitulated these findings and revealed enhanced DNA damage compared to leukemia cells expressing wild type FUBP1 levels. FUBP1 was more highly expressed in human CML compared to normal bone marrow cells and its expression correlated with disease progression. In AML, higher FUBP1 expression in patient leukemia cells was observed with a trend toward correlation with shorter overall survival. Treatment of mice with AML with irinotecan, known to inhibit topoisomerase I and FUBP1, significantly prolonged survival alone or in combination with cytarabine. In summary, our data suggest that FUBP1 acts as cell cycle regulator and apoptosis inhibitor in leukemia. We demonstrated that FUBP1 might play a role in DNA repair, and its inhibition may improve outcome in leukemia patients.
引用
- Hoang VT, Verma D, Godavarthy PS, et al. The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. Leukemia. 2019. PMID: 30635626. doi:10.1038/s41375-018-0358-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。